JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.
JP Morgan Downgrades ResMed to Neutral
JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.
Related Posts
Stress-Related Mood Disorders And Alzheimer’s: Can This Patented Ketamine Drug Help?
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.
Baird Maintains Outperform on Core & Main, Lowers Price Target to $29
Baird analyst David Manthey maintains Core & Main (NYSE:CNM) with a Outperform and lowers the price target from $30 to $29.
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A strains prompt further optimization for influenza B strains.